Shop Now Contact

Anti-Human IL-4Rα (CD124) (Dupilumab Biosimilar)

Cat # Size Price Quantity
5021011 mg$190
5021025 mg$750
50210320 mg$1800

  Bulk/Custom

Product Details

CloneDupilumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionDupilumab Biosimilar, Human IL4R alpha Monoclonal Antibody
IsotypeHuman IgG4
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman IL4R alpha
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsIL-4 receptor alpha
Target NameCD124, IL-4Ra
Antibody TypeRecombinant
Research AreasB cells, Th2 cells, Early Thymocytes, Double Positive Cells
See All FormatsClone Dupilumab

Background Information

Dupilumab is a fully human monoclonal antibody belonging to the immunoglobulin G4 (IgG4) subclass, designed to target the alpha subunit of the interleukin-4 receptor (IL-4Rα). Structurally, it is a glycoprotein composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds, forming the typical Y-shaped structure characteristic of IgG antibodies, with a molecular weight of approximately 147 kilodaltons (kDa). It is produced in mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, which allow proper folding, assembly, and glycosylation consistent with human antibody properties.

The variable regions of Dupilumab’s heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) responsible for binding specifically to human IL-4Rα. This receptor subunit is shared by both the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways. Through high-affinity, non-covalent interactions involving hydrogen bonding and hydrophobic contacts, Dupilumab binds to IL-4Rα in a manner that sterically blocks the receptor’s interaction with both interleukin ligands. This inhibits signaling through the type I receptor complex (IL-4Rα/γc) and the type II receptor complex (IL-4Rα/IL-13Rα1), which are responsible for activating intracellular Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways, particularly STAT6. The interruption of these cascades alters gene expression patterns associated with cytokine-mediated immune regulation in experimental systems.

The Fc region of Dupilumab, consistent with IgG4 isotype antibodies, has been engineered with an S228P substitution in the hinge region to enhance structural stability and prevent half-molecule exchange. This IgG4 backbone minimizes effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation while maintaining extended serum half-life through interaction with the neonatal Fc receptor (FcRn).

Data Sheets

Anti-Human IL-4Rα (CD124) (Dupilumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Anti-Human IL-4 Antibody, Clone MP4-25D2

iF647 Anti-Human IL-4 Antibody, Clone MP4-25D2

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.